#ECTRIMS2021

October 25, 2021 Columns by Ed Tobias

MS News That Caught My Eye Last Week: AHSCT, Ocrevus, CD20 T-cells, Spasticity App

National MS Society Supports Stem Cell Transplant for Select, Aggressive RRMS Bravo! This statement is welcome after the recommendation of National Multiple Sclerosis Society advisers that autologous hematopoietic stem cell transplant, or AHSCT, could be useful for people younger than 50 and recently diagnosed with MS. Now, how long…

October 20, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – App’s Use Prolongs Gains of Spasticity Rehab Program

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Four…

October 19, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – CD20-positive T-cells May Be Early Drivers of MS

October 19, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Problems in Thalamus Linked to Severe Progressive MS

October 19, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Spinal Cord Lesions Predictive of SPMS Conversion in CIS

October 19, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Nrg-1-treated Immune Cells Can Promote Myelin Repair

October 18, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Early Ocrevus Slows MS Better Versus 2-year Delay

October 18, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Economic Burden of MS in US Exceeded $85B in 2019

October 18, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Relapse-free Worsening More Likely in Late-onset MS

October 18, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Ublituximab Better Than Aubagio at Reducing Disability

October 15, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression

October 15, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Sativex Eases MS Patients’ Spasticity, Spasms in Trials

October 15, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Lower Relapse Rates Seen With Tysabri Than Ocrevus

October 15, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Stem Cell Transplant May Better Treat SPMS Than DMTs

October 14, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Brain Lesions Help Predict Long-term Disability

October 14, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Childhood Sexual, Emotional Abuse Increases MS Risk

October 13, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Ponvory Effective in Early MS in OPTIMUM Trial

October 13, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 — Rituximab as First RRMS Therapy Outperforms Others

October 6, 2021 News by Marisa Wexler, MS

#ECTRIMS2021 – Trial Analyses Support Evobrutinib for Relapsing MS

Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…

September 30, 2021 News by Steve Bryson, PhD

#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

#ECTRIMS2021

MS News That Caught My Eye Last Week: AHSCT, Ocrevus, CD20 T-cells, Spasticity App

#ECTRIMS2021 – App’s Use Prolongs Gains of Spasticity Rehab Program

#ECTRIMS2021 – CD20-positive T-cells May Be Early Drivers of MS

#ECTRIMS2021 – Problems in Thalamus Linked to Severe Progressive MS

#ECTRIMS2021 – Spinal Cord Lesions Predictive of SPMS Conversion in CIS

#ECTRIMS2021 – Nrg-1-treated Immune Cells Can Promote Myelin Repair

#ECTRIMS2021 – Early Ocrevus Slows MS Better Versus 2-year Delay

#ECTRIMS2021 – Economic Burden of MS in US Exceeded $85B in 2019

#ECTRIMS2021 – Relapse-free Worsening More Likely in Late-onset MS

#ECTRIMS2021 – Ublituximab Better Than Aubagio at Reducing Disability

#ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression

#ECTRIMS2021 – Sativex Eases MS Patients’ Spasticity, Spasms in Trials

#ECTRIMS2021 – Lower Relapse Rates Seen With Tysabri Than Ocrevus

#ECTRIMS2021 – Stem Cell Transplant May Better Treat SPMS Than DMTs

#ECTRIMS2021 – Brain Lesions Help Predict Long-term Disability

#ECTRIMS2021 – Childhood Sexual, Emotional Abuse Increases MS Risk

#ECTRIMS2021 – Ponvory Effective in Early MS in OPTIMUM Trial

#ECTRIMS2021 — Rituximab as First RRMS Therapy Outperforms Others

#ECTRIMS2021 – Trial Analyses Support Evobrutinib for Relapsing MS

#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination

Recent Posts

Subscribe to our newsletter